Previous 10 | Next 10 |
BeiGene press release (NASDAQ:BGNE): Q4 GAAP EPADS of -$6.16 misses by $1.29. Revenue of $214M (+113.8% Y/Y) beats by $0.64M. Cash, Cash Equivalents, Restricted Cash and Short-Term Investments were $6.62 billion as of December 31, 2021, compared to $3.92 billion as of September 30, 2021, and ...
Recorded product revenue of $196.8 million and $634.0 million for the fourth quarter and full year, respectively, representing a 96.6% and 105.3% increase from $100.1 million and $308.9 million in the prior year periods BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: ...
The U.S. Food and Drug Administration (FDA) accepted BeiGene's (NASDAQ:BGNE) application seeking approval of Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. CLL is a type of cancer of the blood and bone...
The CLL filing is supported by two global Phase 3 trials of BRUKINSA in chronic lymphocytic leukemia covering both treatment-naïve and relapsed or refractory patient populations BRUKINSA was granted approval by the European Commission for the treatment of Waldenström...
The filing is supported by two global Phase 3 trials of BRUKINSA in chronic lymphocytic leukemia covering both treatment-naïve and relapsed or refractory patient populations The Prescription Drug User Fee Act target action date is October 22, 2022 BeiGene (N...
BeiGene's (NASDAQ:BGNE) Brukinsa (zanubrutinib) was approved by Swissmedic to treat adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior line of therapy or for patients who have not received treatment and are not suited for standard chemo-i...
With this approval, BRUKINSA is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing ...
The FDA has expressed concerns that trials supporting drugs to be marketed in the U.S. that are conducted in China do not meet quality standards, The Wall Street Journal reported. In addition, the agency is worried whether studies conducted in Chinese patients are applicable to their American...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET. A live webcast can be...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...